^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CD19/CD22 CAR T-cells

i
Other names: CD19/CD22 CAR T-cells, CD19/CD22 bicistronic chimeric antigen receptor (CAR) T cells
Associations
Company:
National Cancer Institute
Drug class:
CD19-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
Related drugs:
Associations
over1year
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma (clinicaltrials.gov)
P1/2, N=0, Withdrawn, M.D. Anderson Cancer Center | N=30 --> 0 | Trial completion date: Aug 2023 --> Nov 2022 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2023 --> Nov 2022
Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • CAR T-Cell Therapy • Metastases • Immune cell
|
CD22 (CD22 Molecule)
|
CD22 positive
|
cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells
almost2years
Enrollment change
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 expression
|
cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells
over2years
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma (clinicaltrials.gov)
P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Aug 2022 --> Aug 2023
Trial primary completion date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells
almost3years
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (clinicaltrials.gov)
P1, N=87, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2032 --> Dec 2040 | Trial primary completion date: Dec 2022 --> Dec 2025
Trial completion date • Trial primary completion date
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 expression
|
cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells
almost3years
Trial primary completion date
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 expression
|
cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells